Kapstone Financial Advisors LLC Has $1.14 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Kapstone Financial Advisors LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 3.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,568 shares of the company’s stock after selling 261 shares during the quarter. Johnson & Johnson accounts for about 0.6% of Kapstone Financial Advisors LLC’s investment portfolio, making the stock its 28th biggest holding. Kapstone Financial Advisors LLC’s holdings in Johnson & Johnson were worth $1,144,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. IFS Advisors LLC boosted its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $35,000. Activest Wealth Management bought a new stake in shares of Johnson & Johnson in the third quarter worth $40,000. Finally, Fiduciary Advisors Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $43,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on JNJ shares. Guggenheim boosted their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Bank of America boosted their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Price Performance

Shares of JNJ opened at $165.22 on Thursday. The firm has a market capitalization of $397.79 billion, a PE ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. The company’s 50-day moving average is $152.11 and its 200-day moving average is $156.19. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.29 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.